The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Global stocks advance on coronavirus treatment hopes, dollar gains

Mon, 24th Aug 2020 21:12

(Adds close of U.S. markets)

* S&P 500, Nasdaq set all-time peaks

* Apple shares cross $500, Alibaba at record high

* Dollar gains on optimism over COVID-19 treatments

* Gulf of Mexico storms lift crude oil futures

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

By Herbert Lash

NEW YORK, Aug 24 (Reuters) - A gauge of global equity
markets raced toward a record high on Monday in a rally that
lifted the S&P 500 and Nasdaq to all-time peaks and buoyed the
dollar as hopes for coronavirus treatments bolstered risk
appetite.

U.S. regulators on Sunday authorized the use of blood plasma
from recovered COVID-19 patients as a treatment option. Shares
of AstraZeneca rose on a Financial Times report that the U.S.
government was considering fast-tracking its experimental
vaccine.

The U.S. Food and Drug Administration's move to give
emergency authorization for the use of anti-body rich plasma was
hailed by President Donald Trump. It came a day after he accused
the FDA of impeding the roll-out of treatments until after the
Nov. 3 presidential election.

The World Health Organization was cautious about endorsing
the use of the plasma to treat those who are ill, saying
evidence that it works remains "low quality."

The announcement came on the eve of the Republican National
Convention. Trump on Monday received enough votes to formally
win the nomination as the Republican candidate for the
presidency for another four years.

Progress in treatments or an effective vaccine to gain
control of the virus would aid Trump's re-election chances.

Craig Erlam, senior market analyst at OANDA in London, said
that while it was a highly political move on Trump's part,
"everyone wants to be the first to market, everyone wants to get
the economy back on track and slow down the death rate."

"When you add it all up, it's positive COVID news for the
market," he said.

Equity markets worldwide rose on the vaccine hopes. Europe's
broad FTSEurofirst 300 index closed up 1.62% at
1,439.54, while MSCI's all-country world index
rose 1.06% to 577.02 after overnight gains in Asia.

The benchmark for global equity markets is less than 1%
from scaling its all-time peak reached in February.

AstraZeneca rose 2.1%, providing the FTSE 100
index in London its biggest boost.

Shares of Apple Inc rose 1.3% to cross $500 for the
first time, while Chinese retailer Alibaba's U.S.-listed shares
climbed 3.8%, to a record high. Shares of electric
carmaker also set a new high before retreating 1.8%.

On Wall Street, the Dow Jones Industrial Average rose
1.35%, the S&P 500 gained 1.00%, and the Nasdaq Composite
added 0.6%.

The dollar edged higher, holding above two-year lows against
the euro, as its sell-off against the single currency paused
after the U.S. currency got a boost on Friday. Data showed a
recovery in U.S. business conditions, while European data showed
slowing improvement.

Federal Reserve Chairman Jerome Powell this week will give a
highly anticipated speech about the U.S. central bank's policy
framework review at the Fed's annual Jackson Hole symposium.

The speech will be watched for clues about interest rates
and will likely be the next major dollar driver, with investors
watching to see if Powell signals that the Fed will shift its
inflation target to an average.

The 10-year U.S. Treasury note rose 1.4 basis
points to 0.6542%.

The dollar index rose 0.113%, with the euro
down 0.05% to $1.1789.

The Japanese yen weakened 0.12% versus the greenback
at 105.96 per dollar.

Oil prices strengthened as storms threatening the Gulf of
Mexico shut more than half of the U.S. region's oil production
and on expectations of progress in the development of a COVID-19
treatment.

Brent crude futures settled up 78 cents at $45.13 a
barrel. U.S. crude futures rose 28 cents to settle at
$42.62 a barrel.

Gold prices fell as optimism over the FDA's authorization of
a COVID-19 treatment lifted Wall Street stocks to record highs.
U.S. gold futures settled down 0.4% at $1,939.20 an
ounce.

(Reporting by Herbert Lash; Editing by Dan Grebler and Leslie
Adler)

More News
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.